HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples